SOCRA CCRP Practice Exam (Sample)

Study Guide

Everything you need from our exam experts!

Questions

1. What is the purpose of QA in clinical trials?

- **A. To minimize financial costs**
- **B. To publish results quickly**
- **C. To ensure trials are performed and data generated in compliance with GCP**
- **D. To fast-track regulatory approval**

2. How many criteria does the FDA require of Phase 2 and 3 protocols?

- **A. 3**
- **B. 5**
- **C. 7**
- **D. 10**

3. What is required in an IRB application regarding inc/exc criteria?

- **A. A detailed plan for data analysis**
- **B. Documentation of IRB meetings**
- **C. Inclusion and exclusion criteria**
- **D. A list of potential side effects**

4. What does CAPA stand for in trial management?

- **A. Corrective and Preventative Action Plan**
- **B. Comprehensive Action Plan Assessment**
- **C. Clinical Assessment and Planning Application**
- **D. Corrective Action Preventative Assessment**

5. Which statement is true about the criteria for involving children in greater than minimal risk research with prospect of benefit?

- **A. Benefits do not need to be justified**
- **B. The relation of anticipated benefit must be favorable compared with alternative approaches**
- **C. Parental consent isn't necessary**
- **D. Children's assent isn't considered important**

6. How soon must a sponsor conduct investigations of Unanticipated Adverse Device Effects?

- **A. Within 10 days**
- **B. Immediately**
- **C. Within 21 days**
- **D. Within 30 days**

7. What action does a sponsor take to comply with informed consent regulations?

- **A. Provides participants with financial incentives**
- **B. Ensures FDA and all investigators are informed of new AEs or risks**
- **C. Provides investigators with the information they need**
- **D. Maintains the Investigational New Drug application (IND)**

8. What is the definition of a Non-Significant Risk device?

- **A. Does not meet criteria of a significant risk device**
- **B. Is of minimal risk**
- **C. Requires FDA approval before study**
- **D. Is for temporary external use**

9. What form is used to communicate FDA audit findings?

- **A. FDA Form 483**
- **B. FDA Form 990**
- **C. FDA Form 1020**
- **D. FDA Audit Report**

10. What is required for Phase 1 protocols according to the FDA?

- **A. Final results**
- **B. General outline of planned investigation**
- **C. Detailed financial disclosures**
- **D. Comprehensive risk analysis**

Answers

1. C
2. C
3. C
4. A
5. B
6. B
7. B
8. A
9. A
10. B

Explanations

1. What is the purpose of QA in clinical trials?

A. To minimize financial costs

B. To publish results quickly

C. To ensure trials are performed and data generated in compliance with GCP

D. To fast-track regulatory approval

Quality Assurance (QA) plays a critical role in clinical trials as it helps ensure that all aspects of the trial are conducted in compliance with Good Clinical Practice (GCP). GCP is a set of international guidelines that aim to protect the rights, safety, and well-being of trial participants, as well as ensure the credibility and reliability of the data generated. Options A, B, and D do not directly address the main purpose of QA in clinical trials, making them incorrect choices. While minimizing financial costs and fast-tracking regulatory approval may be potential benefits of effective QA, these are not the main purpose of QA in clinical trials. Similarly, publishing results quickly may be desirable, but it should not take priority over ensuring compliance with ethical and scientific standards. Option C is the most accurate choice as it directly relates to the main purpose of QA in clinical trials.

2. How many criteria does the FDA require of Phase 2 and 3 protocols?

A. 3

B. 5

C. 7

D. 10

The FDA requires 7 criteria for Phase 2 and 3 protocols. Option A, B, and D are incorrect because they do not meet the required criteria. Option A is too low, B is slightly low, and D is too high. It is important to pay attention to detail when working with FDA protocols to ensure that they meet the required standards.

3. What is required in an IRB application regarding inc/exc criteria?

A. A detailed plan for data analysis

B. Documentation of IRB meetings

C. Inclusion and exclusion criteria

D. A list of potential side effects

Inclusion and exclusion criteria are essential components of an IRB (Institutional Review Board) application because they define the specific characteristics that determine who can and cannot participate in a clinical trial. These criteria help ensure that the study population is appropriate for the research question being investigated and that the safety and welfare of participants are adequately protected. By providing clear inclusion and exclusion criteria, researchers can ensure that they are recruiting a representative sample, minimize potential risks, and enhance the validity of the study's findings. This helps IRBs evaluate whether the study design is ethical and whether the potential benefits of the research outweigh any risks to participants. The other aspects of the question, such as a detailed plan for data analysis, documentation of IRB meetings, or a list of potential side effects, while relevant to the broader context of a research study, do not directly address the foundational requirements for participant selection and protection, which inclusion and exclusion criteria specifically pertain to.

4. What does CAPA stand for in trial management?

A. Corrective and Preventative Action Plan

B. Comprehensive Action Plan Assessment

C. Clinical Assessment and Planning Application

D. Corrective Action Preventative Assessment

The other options are incorrect because they do not accurately describe the full meaning of CAPA. Option B combines two words from the correct answer but does not include the important term "action." Option C uses different words and adds "Clinical" which is not included in the acronym. Option D rearranges the words and changes "and" to "Action" which does not accurately reflect the meaning of the acronym. Overall, these options do not fully capture the meaning of CAPA, which is a plan for taking corrective and preventative actions in trial management.

5. Which statement is true about the criteria for involving children in greater than minimal risk research with prospect of benefit?

A. Benefits do not need to be justified

B. The relation of anticipated benefit must be favorable compared with alternative approaches

C. Parental consent isn't necessary

D. Children's assent isn't considered important

When involving children in research, it is important to consider the level of risk and potential benefits. Benefits do not need to be justified as they always need to outweigh the risks. Parental consent is absolutely necessary as children cannot legally give their consent. Children's assent is also important but not considered as crucial as parental consent. Therefore, the most important consideration is whether the anticipated benefits outweigh the risks and if the chosen approach is favorable compared to alternative methods. This ensures that the research is ethical and in the best interest of the child.

6. How soon must a sponsor conduct investigations of Unanticipated Adverse Device Effects?

A. Within 10 days

B. Immediately

C. Within 21 days

D. Within 30 days

Sponsors are required to conduct investigations of Unanticipated Adverse Device Effects immediately, as they are considered significant and unexpected events that may lead to harm or injury to a patient. This requires quick action in order to properly gather information and assess the impact of the adverse effect. Options A, C, and D all provide timelines that are longer than immediately and may delay necessary actions and responses. It is important for sponsors to act swiftly in these situations to ensure the safety and well-being of patients.

7. What action does a sponsor take to comply with informed consent regulations?

A. Provides participants with financial incentives

B. Ensures FDA and all investigators are informed of new AEs or risks

C. Provides investigators with the information they need

D. Maintains the Investigational New Drug application (IND)

A sponsor takes several actions to comply with informed consent regulations, including providing participants with all necessary information and obtaining their voluntary consent. Option A is incorrect because providing financial incentives can be seen as coercive and may interfere with the participant's ability to make an informed decision. Option C is incorrect because it is the responsibility of the investigator, not the sponsor, to provide information to other investigators. Option D is incorrect because maintaining the Investigational New Drug application (IND) is a requirement for conducting clinical trials but has no direct relation to informed consent regulations. Option B is the correct answer because by ensuring that the FDA and investigators are informed of any new adverse events or risks, the sponsor is ensuring that participants are fully informed and protected.

8. What is the definition of a Non-Significant Risk device?

A. Does not meet criteria of a significant risk device

B. Is of minimal risk

C. Requires FDA approval before study

D. Is for temporary external use

A non-significant risk device is one that does not meet the criteria of a significant risk device. This means that it does not pose a significant risk to the health, safety, or wellbeing of the patient. Option B is incorrect because "minimal risk" is not a defined term in this context. Option C is incorrect because all medical devices require FDA approval before being marketed in the US. Option D is incorrect because the temporary or external use of a device does not determine its risk classification.

9. What form is used to communicate FDA audit findings?

A. FDA Form 483

B. FDA Form 990

C. FDA Form 1020

D. FDA Audit Report

FDA Form 483 is the most commonly used form to communicate FDA audit findings. It is used to document and communicate any observations and deviations found during an FDA inspection to a company. This form is used by the FDA to inform the company of any potential violations and to request a response from the company on how they plan to address and correct these issues. Option B, FDA Form 990, is a tax document that is used by certain tax-exempt organizations and non-profits to report their financial information to the Internal Revenue Service (IRS). This form has no relation to FDA audit findings. Option C, FDA Form 1020, does not exist. This may have been a distractor choice. Option D, FDA Audit Report, is a generic term that can refer to any report that is generated as a result of an FDA audit. It is not a specific form and is not typically

10. What is required for Phase 1 protocols according to the FDA?

A. Final results

B. General outline of planned investigation

C. Detailed financial disclosures

D. Comprehensive risk analysis

According to the FDA, a general outline of the planned investigation is required for Phase 1 protocols. This is because Phase 1 trials are used to study the initial safety and tolerability of a new drug or treatment on a small group of healthy volunteers. Final results would not be available before starting the trial, so they are not required at this stage. Detailed financial disclosures and a comprehensive risk analysis may be necessary in later phases, but they are not directly related to the initial review and approval process for Phase 1 protocols. Therefore, they are not required at this stage.